Luye Pharma Reports 1H 2025 Revenue Growth of 3.5 % Amid Oncology and CNS Gains
Company

Luye Pharma Reports 1H 2025 Revenue Growth of 3.5 % Amid Oncology and CNS Gains

Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge
Company

Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge

Zennova & Rapafusyn Forge BioCarier‑Powered RapaGlue Collaboration – 2025
CompanyDeals

Zennova & Rapafusyn Forge BioCarier‑Powered RapaGlue Collaboration – 2025

Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China
CompanyDrug

Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China

Innovent Biologics Revenue Soars 50% in H1 2025 – Oncology Growth Fuels GLP‑1 Expansion
Company

Innovent Biologics Revenue Soars 50% in H1 2025 – Oncology Growth Fuels GLP‑1 Expansion

NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed
Policy / Regulatory

NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed

HarbourBioMed Reports 327 % Revenue Surge, Launches HCAb‑Based Élancé Therapeutics
Company

HarbourBioMed Reports 327 % Revenue Surge, Launches HCAb‑Based Élancé Therapeutics

Santen Receives Boao Lecheng Approval for RYJUSEA – A Preservative‑Free Atropine Eye Drop for Pediatric Myopia
CompanyDrug

Santen Receives Boao Lecheng Approval for RYJUSEA – A Preservative‑Free Atropine Eye Drop for Pediatric Myopia

Anglikang Secures Exclusive Rights to Yafei’s IMD‑1005 in China
CompanyDeals

Anglikang Secures Exclusive Rights to Yafei’s IMD‑1005 in China

RemeGen’s Telitacicept Hits Primary Endpoint in Phase III IgA Nephropathy Trial
CompanyDrug

RemeGen’s Telitacicept Hits Primary Endpoint in Phase III IgA Nephropathy Trial

ImmuneOnco Secures $5 M Milestone from Instil Bio, Strengthening Axion Bio Collaboration
CompanyDeals

ImmuneOnco Secures $5 M Milestone from Instil Bio, Strengthening Axion Bio Collaboration

Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3‑Year Profit Trend
Company

Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3‑Year Profit Trend